About US
Contact us
-
FDA approves Omidria for use in intraoperative lens replacement surgeryOmeros has received approval from the US Food and Drug Administration (FDA) for its Omidria for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraop2014/6/6
-
Bayer signs agreement with Orion to develop prostate cancer drugGermany-based Bayer and Finland-based Orion have signed a global agreement to develop and commercialise the investigational oral androgen receptor inhibitor, ODM-201, for treating prostate cancer pati2014/6/5
-
FDA grants fast-track designation to Angiochem’s glioblastoma multiforme drugAngiochem has received fast-track and orphan drug designations from the US Food and Drug Association (FDA) for its Ang1005 product for treatment of glioblastoma multiforme. Ang1005 is a paclitaxel-pe2014/6/5
-
DFE Pharma Customer Value Management Survey: coming soonDear customer Your experience with DFE Pharma is something we are always looking to improve. The DFE Pharma biennialCustomer Value Management Survey is a key source of insights on how we’re performin2014/6/4
-
Adaptimmune and GSK enter into collaboration for NY-ESO-1 clinical cancer programmeUK-based Adaptimmune has entered into a strategic cancer immunotherapy collaboration with GlaxoSmithKline (GSK) to develop and commercialise Adaptimmune's NY-ESO-1 clinical cancer programme. Under th2014/6/4
-
Eisai's antiemetic agent Aloxi gets FDA approval to treat childrenJapan-based Eisai has received approval from the US Food and Drug Administration (FDA) for antiemetic agent Aloxi (palonosetron HCI) as an additional indication for preventing acute nausea and vomitin2014/6/4
-
Newron submits new drug application to FDA for Parkinson's disease treatmentNewron Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for safinamide, which is being developed as an add-on therapy to dopamine agonists or to2014/6/3
-
Eisai's antiemetic agent Aloxi gets FDA approval to treat childrenJapan-based Eisai has received approval from the US Food and Drug Administration (FDA) for antiemetic agent Aloxi (palonosetron HCI) as an additional indication for preventing acute nausea and vomitin2014/6/3
-
Bristol-Myers Squibb collaborates with CytomX on immuno-oncology targetsBristol-Myers Squibb has signed a worldwide research collaboration and licence agreement with CytomX Therapeutics to discover, develop and commercialise new therapies using CytomX's Probody platform a2014/5/30
-
Celerion and KDDF sign agreement to advance drug discovery in South KoreaUS-based Celerion and the Korean Drug Development Fund (KDDF) have signed a collaboration agreement aimed at strengthening early phase clinical research in South Korea. A memorandum of understanding2014/5/30